Immuno-mass Spectrometric Identification of Predictive Biomarkers of Response and/or Toxicity to Immune Checkpoint Inhibitors
Year: 2019
Type: dissertation
Study design: Observational Study
Abstract: Immune checkpoint inhibitors (ICIs) are humanized antibodies that target specific inhibitory molecules, such as programmed cell death protein 1 (PD-1) and its ligand, PD-L1. The limitations of ICIs are high cost, limited response rate and development of immune-related adverse events (irAEs). Predictive and monitoring biomarkers of ICIs are an unmet need. We hypothesized that patients who develop irAEs will produce specific autoantibodies indicative of an autoimmune-like response. We developed a novel methodology that involves immunoaffinity purification of serum autoantibodies, incubation with target autoantigens and mass spectrometric identification of autoantibody targets. Using our methodology and electrochemiluminescence immunoassay for validation, we found that patients treated with pembrolizumab have anti-thyroglobulin antibody titers that are significantly associated with irAE development. Furthermore, we identified several potential autoantibody targets in a patient with ICI-induced myocarditis. Predictive biomarkers of ICIs will save significant resources, ensure proper patient selection for treatment, and spare certain patients from irAEs.
Source: TSpace (University of Toronto)
Author: Milena Music
Institution: University of Toronto
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3152720025
